|
Gene: SKI |
Gene summary for SKI |
Gene summary. |
Gene information | Species | Human | Gene symbol | SKI | Gene ID | 6497 |
Gene name | SKI proto-oncogene | |
Gene Alias | SGS | |
Cytomap | 1p36.33-p36.32 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P12755 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6497 | SKI | LZE7T | Human | Esophagus | ESCC | 2.91e-05 | 2.53e-02 | 0.0667 |
6497 | SKI | LZE8T | Human | Esophagus | ESCC | 3.04e-06 | -2.10e-02 | 0.067 |
6497 | SKI | LZE24D1 | Human | Esophagus | HGIN | 1.88e-03 | 3.97e-01 | 0.054 |
6497 | SKI | LZE24T | Human | Esophagus | ESCC | 7.94e-05 | 6.44e-02 | 0.0596 |
6497 | SKI | P1T-E | Human | Esophagus | ESCC | 2.62e-04 | 5.29e-02 | 0.0875 |
6497 | SKI | P2T-E | Human | Esophagus | ESCC | 1.00e-14 | 2.93e-01 | 0.1177 |
6497 | SKI | P4T-E | Human | Esophagus | ESCC | 1.79e-06 | 1.46e-01 | 0.1323 |
6497 | SKI | P5T-E | Human | Esophagus | ESCC | 1.27e-12 | -3.21e-02 | 0.1327 |
6497 | SKI | P8T-E | Human | Esophagus | ESCC | 1.12e-18 | 4.26e-01 | 0.0889 |
6497 | SKI | P9T-E | Human | Esophagus | ESCC | 1.37e-10 | 2.68e-02 | 0.1131 |
6497 | SKI | P10T-E | Human | Esophagus | ESCC | 2.55e-11 | 3.13e-01 | 0.116 |
6497 | SKI | P11T-E | Human | Esophagus | ESCC | 6.32e-11 | 9.20e-02 | 0.1426 |
6497 | SKI | P12T-E | Human | Esophagus | ESCC | 7.72e-10 | 2.74e-01 | 0.1122 |
6497 | SKI | P15T-E | Human | Esophagus | ESCC | 8.66e-11 | 1.12e-01 | 0.1149 |
6497 | SKI | P16T-E | Human | Esophagus | ESCC | 9.05e-15 | 1.43e-01 | 0.1153 |
6497 | SKI | P20T-E | Human | Esophagus | ESCC | 5.25e-10 | 4.43e-02 | 0.1124 |
6497 | SKI | P21T-E | Human | Esophagus | ESCC | 4.21e-19 | 1.77e-01 | 0.1617 |
6497 | SKI | P22T-E | Human | Esophagus | ESCC | 1.64e-09 | -8.58e-02 | 0.1236 |
6497 | SKI | P23T-E | Human | Esophagus | ESCC | 2.27e-04 | 1.16e-01 | 0.108 |
6497 | SKI | P24T-E | Human | Esophagus | ESCC | 1.52e-05 | -1.57e-02 | 0.1287 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | |
Thyroid | goiters | |
Thyroid | ATC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009719310 | Cervix | CC | intrinsic apoptotic signaling pathway | 85/2311 | 288/18723 | 4.56e-15 | 6.46e-12 | 85 |
GO:200123310 | Cervix | CC | regulation of apoptotic signaling pathway | 96/2311 | 356/18723 | 4.08e-14 | 3.05e-11 | 96 |
GO:200124210 | Cervix | CC | regulation of intrinsic apoptotic signaling pathway | 52/2311 | 164/18723 | 5.06e-11 | 1.01e-08 | 52 |
GO:20012357 | Cervix | CC | positive regulation of apoptotic signaling pathway | 37/2311 | 126/18723 | 2.70e-07 | 1.12e-05 | 37 |
GO:009719110 | Cervix | CC | extrinsic apoptotic signaling pathway | 52/2311 | 219/18723 | 2.06e-06 | 6.34e-05 | 52 |
GO:004887210 | Cervix | CC | homeostasis of number of cells | 61/2311 | 272/18723 | 2.17e-06 | 6.55e-05 | 61 |
GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
GO:20012446 | Cervix | CC | positive regulation of intrinsic apoptotic signaling pathway | 20/2311 | 58/18723 | 1.07e-05 | 2.33e-04 | 20 |
GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
GO:200123610 | Cervix | CC | regulation of extrinsic apoptotic signaling pathway | 37/2311 | 151/18723 | 2.80e-05 | 4.65e-04 | 37 |
GO:00017018 | Cervix | CC | in utero embryonic development | 71/2311 | 367/18723 | 7.21e-05 | 1.00e-03 | 71 |
GO:00074097 | Cervix | CC | axonogenesis | 78/2311 | 418/18723 | 1.14e-04 | 1.43e-03 | 78 |
GO:20010209 | Cervix | CC | regulation of response to DNA damage stimulus | 46/2311 | 219/18723 | 1.92e-04 | 2.23e-03 | 46 |
GO:00071786 | Cervix | CC | transmembrane receptor protein serine/threonine kinase signaling pathway | 67/2311 | 355/18723 | 2.39e-04 | 2.67e-03 | 67 |
GO:00507705 | Cervix | CC | regulation of axonogenesis | 34/2311 | 154/18723 | 4.87e-04 | 4.76e-03 | 34 |
GO:00715595 | Cervix | CC | response to transforming growth factor beta | 50/2311 | 256/18723 | 6.31e-04 | 5.91e-03 | 50 |
GO:00715605 | Cervix | CC | cellular response to transforming growth factor beta stimulus | 49/2311 | 250/18723 | 6.55e-04 | 6.05e-03 | 49 |
GO:00086309 | Cervix | CC | intrinsic apoptotic signaling pathway in response to DNA damage | 24/2311 | 99/18723 | 7.93e-04 | 6.99e-03 | 24 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa043507 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0435014 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SKI | SNV | Missense_Mutation | novel | c.644N>T | p.Glu215Val | p.E215V | P12755 | protein_coding | deleterious(0.02) | possibly_damaging(0.81) | TCGA-OL-A5D6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SKI | SNV | Missense_Mutation | c.1435N>A | p.Asp479Asn | p.D479N | P12755 | protein_coding | tolerated(0.06) | benign(0.011) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
SKI | SNV | Missense_Mutation | novel | c.833N>G | p.Ser278Trp | p.S278W | P12755 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-VS-A8QM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
SKI | SNV | Missense_Mutation | rs752151031 | c.1400N>T | p.Thr467Met | p.T467M | P12755 | protein_coding | tolerated(0.15) | benign(0) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
SKI | SNV | Missense_Mutation | c.892G>A | p.Ala298Thr | p.A298T | P12755 | protein_coding | tolerated(0.26) | benign(0.027) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SKI | SNV | Missense_Mutation | c.1670A>T | p.Glu557Val | p.E557V | P12755 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-DC-4749-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SKI | SNV | Missense_Mutation | novel | c.1597N>A | p.Asp533Asn | p.D533N | P12755 | protein_coding | tolerated(0.27) | benign(0.059) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SKI | SNV | Missense_Mutation | novel | c.434A>G | p.Glu145Gly | p.E145G | P12755 | protein_coding | deleterious(0) | possibly_damaging(0.553) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
SKI | SNV | Missense_Mutation | novel | c.1945N>A | p.Val649Met | p.V649M | P12755 | protein_coding | deleterious(0.01) | benign(0.38) | TCGA-AX-A2H4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
SKI | SNV | Missense_Mutation | c.477G>T | p.Glu159Asp | p.E159D | P12755 | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |